Ultragenyx Q1 revenuedrop steeper than estimated; back FY view

Ultragenyx Pharmaceutical

05/05/2026 21:11

Corrects to fix grammar in headline

Overview

US rare disease drugmaker's Q1 revenue fell yr/yr and missed analyst expectations

Company posted wider Q1 net loss of $185 mln, or $1.84 per share

Ultragenyx reaffirmed 2026 revenue and expense guidance, maintains profitability target for 2027

Outlook

Ultragenyx reaffirms 2026 total revenue guidance of $730 mln to $760 mln

Company expects combined R&D and SG&A expenses in 2026 to be flat or slightly down vs 2025

Ultragenyx expects combined R&D and SG&A expenses in 2027 to decrease by at least 15%

Result Drivers

CRYSVITA SEASONALITY - Crysvita revenue reflected expected seasonality in the U.S. and Canada and ordering patterns in Brazil

EVKEEZA GROWTH - Evkeeza revenue rose due to increased demand from new country launches and early access

OPERATING EXPENSES - Operating expenses increased due to higher R&D and restructuring costs

Company press release: ID:nGNXb9Rwf4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$136 mln
$158.78 mln (15 Analysts)
Q1 EPS
-$1.84
Q1 Net Income
-$185 mln
Q1 Operating Expenses
$305 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $50.00, about 101.5% above its May 4 closing price of $24.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)